Patients with rheumatoid arthritis are at an increased risk for venous thromboembolism, regardless of age, sex, BMI, and ...

Vascular toxicity associated with cancer therapies is a leading cause of cardiovascular adverse events in patients with ...

Venous thromboembolism is a common and potentially fatal complication in hospitalized surgical patients and acutely ill medical patients. 1 The benefits of providing pharmacologic ...

Individuals with Raynaud phenomenon and no underlying systemic autoimmune rheumatic diseases have increased risk for ...

Venous thromboembolism is known to be a major preventable cause of morbidity and mortality worldwide. 1 In order to reduce the morbidity and mortality associated with venous thromboembolism, it is ...

Of 1215 patients, 6 of 594 (1.0%) in the idraparinux group and 23 of 621 (3.7%) in the placebo group had recurrent venous thromboembolism (P=0.002). Major bleeding occurred in 11 patients (1.9% ...

Incidences of recurrent VTE and bleeding were low during extended-phase anticoagulant treatment and similar to acute-phase results.

Background: Whether to continue oral anticoagulant therapy beyond 6 months after an “unprovoked” venous thromboembolism is controversial. We sought to determine clinical predictors to identify ...

Venous thromboembolism (VTE), a term referring to blood clots in the veins, is a highly prevalent and far-reaching public health problem that can cause disability and death. Despite effective new ...

(HealthDay News) — Venous thromboembolism (VTE) risk varies across hormonal contraceptives, according to a research letter published online Feb. 10 in the Journal of the American Medical ...

Similarly, the cumulative arterial thromboembolism incidence ranged from 0.06% in the UK and Italy to 0.79% in Spain, further increasing to 3.08% among the hospitalized patients.